TECHWIRE 30
(CIX: WRAL30)  990.01  up arrow+8.5  (0.87 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NQ: Apple)  519.01  up arrow+1.05  (0.2 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NY: QUINTILES)  50.60  down arrow-0.07  (-0.14 %)  Updated: 06:40 PM EDT, Apr 16 2014
(OP: BASF SE)  108.14  up arrow+1.55  (1.45 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NQ: BioCryst)  8.34  up arrow+0.01  (0.12 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NQ: BioDelivery)  7.40  up arrow+0.27  (3.79 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NQ: CEMP)  9.23  up arrow+0.5  (5.73 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NQ: Cisco Systems)  23.03  up arrow+0.14  (0.61 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NQ: Cornerstone)  9.49    (0 %)  Updated: 08:10 PM EST, Feb 03 2014
(NQ: Cree)  56.38  up arrow+0.87  (1.57 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NQ: DARA)  2.48  down arrow-0.02  (-0.8 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NY: EMC CORPORATION)  26.70  down arrow-0.22  (-0.82 %)  Updated: 06:40 PM EDT, Apr 16 2014
(NQ: Extreme Networks)  5.62  down arrow-0.03  (-0.53 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NQ: Facebook)  59.72  up arrow+0.63  (1.07 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NY: GLAXOSMITHKLINE)  52.82  up arrow+0.5  (0.96 %)  Updated: 06:40 PM EDT, Apr 16 2014
(NQ: GOOG)  556.54  up arrow+20.1  (3.75 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NY: IBM)  196.40  down arrow-0.62  (-0.31 %)  Updated: 06:40 PM EDT, Apr 16 2014
(NY: LH)  101.95  up arrow+0.39  (0.38 %)  Updated: 06:40 PM EDT, Apr 16 2014
(OP: Lenovo Group)  24.14  up arrow+0.74  (3.17 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NY: MRK)  56.26  up arrow+0.21  (0.37 %)  Updated: 06:40 PM EDT, Apr 16 2014
(NQ: Microsoft Corp)  40.40  up arrow+0.65  (1.64 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NQ: NetApp)  36.24  down arrow-0.76  (-2.04 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NY: NOVARTIS AG)  84.41  up arrow+0.62  (0.74 %)  Updated: 06:40 PM EDT, Apr 16 2014
(OP: Novozymes A/S)  44.91  up arrow+1.25  (2.86 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NY: PFIZER)  30.09  up arrow+0.2  (0.67 %)  Updated: 06:40 PM EDT, Apr 16 2014
(NQ: Pozen)  8.73  up arrow+0.26  (3.07 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NY: RED HAT)  50.62  up arrow+0.52  (1.04 %)  Updated: 06:40 PM EDT, Apr 16 2014
(NQ: BBRY)  7.15  down arrow-0.06  (-0.83 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NQ: Salix)  100.66  up arrow+2.47  (2.52 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NQ: SQI)  26.00  up arrow+0.97  (3.88 %)  Updated: 08:10 PM EDT, Apr 16 2014

Posts tagged “Novartis”

December 8, 2011

Premium Lock Novartis drug plant in Wilson on FDA warning list

Novartis The U.S. Food and Drug Administration is taking Novartis CEO Joseph Jimenez to task with a warning letter that cites three of the company's manufacturing facilities for "significant violations" at the company's generics drug unit Sandoz.

November 4, 2011

Premium Lock Life science awards go to PPD, Novartis, Steve Burrill

Life science Scrips, an international life science media and related services firm based in the U.K., honors PPD with two awards, Novartis with three, and names Burrill its lifetime achievement winner.

Updated October 25, 2011

Premium Lock Novartis to cut 2,000 jobs, close 3 European plants

The drug giant, which operates a huge vaccine production and research facility in Holly Springs, says some jobs will be moved to the US as well as China and India.

New Novartis plant.  New Novartis plant.

October 20, 2011

Premium Lock Novartis: 'Contagion' is fiction but threat is real

The movie "Contagion" is fiction, but ask Novartis executive Russell Thirsk and he'll tell you the threats it depicts are quite real.

Click here to open the YouTube video in a new window.

September 6, 2011

Premium Lock Novartis fights patent rejection in Indian court

Novartis In a case that could affect India's role as drug provider to the developing world, the Supreme Court began hearing arguments Tuesday over whether the government had the right to deny a patent to Swiss drugmaker Novartis AG for its lifesaving cancer treatment Gleevec.

Tags: Novartis
April 19, 2011

Premium Lock Novartis earnings, sales top analysts' expectations

New Novartis plant.  Net income falls 6 percent but overall sales increase 16 percent from a year ago.

January 24, 2011

Premium Lock Novartis bids $470M for California-based cancer diagnostic firm

Novartis The Swiss drug maker, which is building a huge vaccine production plant in Holy Springs, is buying Genoptix.

December 22, 2010

Premium Lock Novartis to add 100 jobs, facilities at Holly Springs plant

The global life sciences firm will receive up to $3.7 million in state tax incentives for the expansion.

New Novartis plant.  New Novartis plant.

November 16, 2010

Premium Lock Report: Novartis looking to buy as cash improves

Novartis The company is paying down debt from its Alcon purchase and looks to be debt-free in four years, the Financial Times said.

Tags: Novartis
Updated July 1, 2010

Premium Lock What pandemic? $260 million worth of H1N1 vaccine to go up in smoke

H1N1 A whopping 40 million does of the vaccine expires – and another 30 million doses are likely to be unused, federal government says. GSK, Novartis were among the big H1N1 vaccine providers.

Updated April 16, 2010

Premium Lock FDA slaps GSK, Novartis, Astellas for ad, Web claims

GSK Letters sent to the three companies concerned claims made for cancer, pain and bladder-control drugs.

Updated February 22, 2010

Premium Lock Viamet Pharmaceuticals signs license deal with Novartis topping $200M

Morrisville-based firm, which was co-founded by UNC-CH Chancellor Holden Thorp, will work with venture arm of Swiss drug giant in researching potential metal-based enzyme inhibitors.

Viamet Viamet

January 26, 2010

Premium Lock Novartis, which is building $1 billion plant in Holly Springs, names new CEO

Drug giant reports strong earnings. It also will pay a $185 million fine in case involving the marketing of its epilepsy drug Trileptal.

Novartis CEO Joe Jimenez, left, and Chairman Daniel Vasella Novartis CEO Joe Jimenez, left, and Chairman Daniel Vasella

January 4, 2010

Premium Lock Novartis to buy eye-care products maker Alcon in $38.5B deal

Novartis Swiss drug maker, which recently opened massive vaccine plant in Holly Springs, N.C., will buy out remainder of Alcon that is held by Nestle SA and other minority shareholders.

Updated November 24, 2009

Premium Lock It’s opening day for $1 billion Novartis plant in Holly Springs

Mammoth 430,000-square-foot facility could be ready to produce a key ingredient for H1N1 vaccine in December, Swiss company says. Plant will be first in U.S. to produce vaccines based on cell cultures.

New Novartis plant.  New Novartis plant.

Updated October 26, 2009

Premium Lock Novartis to celebrate $600 million Holly Springs plant opening on Nov. 24.

Massive facility will be used for production of H1N1 vaccine. Some 300 people are expected to be hired. Novartis is under contract to produce vaccine for U.S. government.

Novartis' plant in Holly Springs Novartis' plant in Holly Springs

Techwire Inside Partners
The Skinny: A Blog by Rick Smith

OUR INSIDERS

Frank Vinluan
Life science
Dr. Mike Walden
Tech economy
Vivek Wadhwa
Commentary
Scroll